+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

InVivoScribe Technologies Inc - Product Pipeline Analysis, 2020 Update

  • ID: 5240154
  • Company Profile
  • January 2021
  • 37 pages
  • GlobalData

FEATURED COMPANIES

  • Esoterix Inc
  • New England Biolabs Inc
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

InVivoScribe Technologies Inc (InVivoScribe) is a provider of hematology-oncology testing products and services. The company offer full range of hematology-oncology testing products and services. It’s products include lymphotrack and lymphotrack DX assay kits, and custom assay and reagent development products. InVivoScribe also provides general purpose reagents such as PCR and cDNA reagents, gel detection reagents and ABI fluorescence detection reagents. The company offers PCR-based gene rearrangement, chromosome translocation, and gene mutation research use only testing reagents and controls. It provides its in vitro diagnostic cGMP products for hematology-oncology, RUO assays, analyte specific reagents, and DNA and RNA controls. The company operates through research laboratories located in Japan. InVivoScribe is headquartered in San Diego, California, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope
  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company InVivoScribe Technologies Inc
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Esoterix Inc
  • New England Biolabs Inc
InVivoScribe Technologies Inc Company Overview
  • InVivoScribe Technologies Inc Company Snapshot
  • InVivoScribe Technologies Inc Pipeline Products and Ongoing Clinical Trials Overview
  • InVivoScribe Technologies Inc - Pipeline Analysis Overview
  • InVivoScribe Technologies Inc - Key Facts
  • InVivoScribe Technologies Inc - Major Products and Services
  • InVivoScribe Technologies Inc Pipeline Products by Development Stage
  • InVivoScribe Technologies Inc Ongoing Clinical Trials by Trial Status
InVivoScribe Technologies Inc Pipeline Products Overview
  • B-cell Clonality Assay Kit
  • B-cell Clonality Assay Kit Product Overview
  • B-cell Immuno-Oncology Assay Kit
  • B-cell Immuno-Oncology Assay Kit Product Overview
  • Companion Diagnostic Test - Eprenetapopt
  • Companion Diagnostic Test - Eprenetapopt Product Overview
  • LeukoStrat CDx FLT3 Mutation Assay - Gilteritinib Fumarate
  • LeukoStrat CDx FLT3 Mutation Assay - Gilteritinib Fumarate Product Overview
  • LeukoStrat CDx FLT3 Mutation Assay - Quizartinib
  • LeukoStrat CDx FLT3 Mutation Assay - Quizartinib Product Overview
  • LeukoStrat CDx FLT3 Mutation Assay - Quizartinib Clinical Trial
  • LymphoTrack Dx TRB Assay - PGM
  • LymphoTrack Dx TRB Assay - PGM Product Overview
  • MiSeqDx - Cancer Diagnostic Test
  • MiSeqDx - Cancer Diagnostic Test Product Overview
  • NGS Based Hematologic Malignancy Test
  • NGS Based Hematologic Malignancy Test Product Overview
  • T-cell Clonality Assay Kit
  • T-cell Clonality Assay Kit Product Overview
  • T-cell Immuno-Oncology Assay Kit
  • T-cell Immuno-Oncology Assay Kit Product Overview
InVivoScribe Technologies Inc - Key Competitors

InVivoScribe Technologies Inc - Key Employees

InVivoScribe Technologies Inc - Locations and Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Recent Developments
  • InVivoScribe Technologies Inc, Recent Developments
  • Oct 30, 2019: European Commission approves Astellas' XOSPATA for patients with relapsed or refractory Acute Myeloid Leukemia with mutations detected using Invivoscribe's LeukoStrat CDx FLT3 Mutation Assay
  • Jun 19, 2019: Japan’s MHLW approves Invivoscribe’s LeukoStrat CDx FLT3 Mutation Assay as the CDx for Daiichi Sankyo’s Quizartinib for treatment of Relapsed/Refractory FLT3-ITD AML. Expands use to include specimens collected in EDTA
  • Jun 03, 2019: Invivoscribe to exhibit at ASCO 2019
  • May 21, 2019: Invivoscribe Expanding Clinical Laboratory Network Space and Testing Capabilities in San Diego, Germany, Japan, and China
  • Jan 23, 2019: Invivoscribe LymphoTrack Dx Assays now available
  • Jan 03, 2019: Invivoscribe to present at biotech showcase 2019 in San Francisco
  • Nov 29, 2018: US FDA approves Invivoscribe LeukoStrat CDx FLT3 Mutation Assay as CDx and Astellas drug XOSPATA (gilteritinib fumarate) for treatment of AML patients in the US
  • Nov 27, 2018: Invivoscribe submits LeukoStrat CDx FLT3 Mutation Assay both in the US and Japan to support Daiichi Sankyo submissions for Quizartinib
  • Nov 19, 2018: Invivoscribe submits the LeukoStrat CDx FLT3 Mutation Assay to support Daiichi Sankyo submission for Quizartinib in Japan
  • Sep 28, 2018: Invivoscribe receives approval in Japan for its LeukoStrat CDx FLT3 Mutation Assay for the assessment of acute myeloid leukemia (AML) patients treated with Xospata (gilteritinib fumarate)
Appendix
  • Methodology
  • About the Publisher
  • Contact Us
  • Disclaimer
List of Tables
  • InVivoScribe Technologies Inc Pipeline Products and Ongoing Clinical Trials Overview
  • InVivoScribe Technologies Inc Pipeline Products by Equipment Type
  • InVivoScribe Technologies Inc Pipeline Products by Indication
  • InVivoScribe Technologies Inc Ongoing Clinical Trials by Trial Status
  • InVivoScribe Technologies Inc, Key Facts
  • InVivoScribe Technologies Inc, Major Products and Services
  • InVivoScribe Technologies Inc Number of Pipeline Products by Development Stage
  • InVivoScribe Technologies Inc Pipeline Products Summary by Development Stage
  • InVivoScribe Technologies Inc Ongoing Clinical Trials by Trial Status
  • InVivoScribe Technologies Inc Ongoing Clinical Trials Summary
  • B-cell Clonality Assay Kit - Product Status
  • B-cell Clonality Assay Kit - Product Description
  • B-cell Immuno-Oncology Assay Kit - Product Status
  • B-cell Immuno-Oncology Assay Kit - Product Description
  • Companion Diagnostic Test - Eprenetapopt - Product Status
  • Companion Diagnostic Test - Eprenetapopt - Product Description
  • LeukoStrat CDx FLT3 Mutation Assay - Gilteritinib Fumarate - Product Status
  • LeukoStrat CDx FLT3 Mutation Assay - Gilteritinib Fumarate - Product Description
  • LeukoStrat CDx FLT3 Mutation Assay - Quizartinib - Product Status
  • LeukoStrat CDx FLT3 Mutation Assay - Quizartinib - Product Description
  • LeukoStrat CDx FLT3 Mutation Assay - Quizartinib - A Phase 3 Open-label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects with Tyrosine Kinase 3 - Internal Tandem Duplication (FLT3-ITD) Positive Acute Myeloid Leukemia (AML) Refractory to or Relapsed after First-line Treatment with or without Hematopoietic Stem Cell Transplantation (HSCT) Consolidation
  • LymphoTrack Dx TRB Assay - PGM - Product Status
  • LymphoTrack Dx TRB Assay - PGM - Product Description
  • MiSeqDx - Cancer Diagnostic Test - Product Status
  • MiSeqDx - Cancer Diagnostic Test - Product Description
  • NGS Based Hematologic Malignancy Test - Product Status
  • NGS Based Hematologic Malignancy Test - Product Description
  • T-cell Clonality Assay Kit - Product Status
  • T-cell Clonality Assay Kit - Product Description
  • T-cell Immuno-Oncology Assay Kit - Product Status
  • T-cell Immuno-Oncology Assay Kit - Product Description
  • InVivoScribe Technologies Inc, Key Employees
  • InVivoScribe Technologies Inc, Subsidiaries
  • Glossary
List of Figures
  • InVivoScribe Technologies Inc Pipeline Products by Equipment Type
  • InVivoScribe Technologies Inc Pipeline Products by Development Stage
  • InVivoScribe Technologies Inc Ongoing Clinical Trials by Trial Status
Note: Product cover images may vary from those shown
  • Bay Area Biotechnology Education Consortium
  • New England Biolabs Inc
  • Esoterix Inc
Note: Product cover images may vary from those shown
Adroll
adroll